Minimal residual disease: a key determinant of ALL treatment response

Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is now considered to be an equal, or greater, marker in predicting patient outcomes. MRD can aid in tailoring therapies a... Author: VJOncology Added: 05/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts